Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

Inclusion Criteria: * Adult subjects ≥18 to ≤55 years of age * Willing and able to provide written informed consent Exclusion Criteria: * Presence of clinically significant physical, laboratory, or ECG findings that, in the opinion of the Investigator and/or Sponsor, may interfere with any aspect of study conduct or interpretation of results * Existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of LX4211 * History of renal disease, or significantly abnormal kidney function test at Screening * History of hepatic disease, or significantly abnormal liver function tests at Screening * History of any clinically relevant psychiatric, renal, hepatic, pancreatic, endocrine, cardiovascular, neurological, hematological, or GI abnormality